Ketamine nasal spray for depression restricted to trained providers
More than 20 clinics around Australia are offering the therapy to patients with treatment-resistant depression.
Archives: news
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities
Cybin Inc., today announced it has awarded a grant for the first psychedelic treatment clinic at Lenox Hill Hospital, part of Northwell Health, to serve marginalized and underserved communities on the Upper East Side of Manhattan, New York.
Pasithea Therapeutics Brings New Depression Treatments To London
With on-the-ground operations in both the United States and United Kingdom, Pasithea Therapeutics is working to bring treatments for depression and other mental health disorders to more people. Through a partnership with Zen Healthcare, Pasithea recently opened a clinic in the heart of Knightsbridge.
Psychedelic Companies Keenly Aware Of Creating Therapies As Healthcare Reimbursement Possibility Looms
In the quest to design effective and affordable psychedelic treatments for a range of maladies that include PTSD and depression, one key thought on the minds of company executives and clinicians alike seems to be how to motivate healthcare insurance companies to cover the cost of psychedelic therapies.
Love Pharma Signs Letter of Intent to Acquire 100% Interest in MicrDoz Therapy Inc. To Expedite Pilot Study of Psilocybin Assisted Treatment of Cannabis Use Disorder with World Leading University
LOVE Pharma Inc. is pleased to announce that it has executed a Letter of Intent to acquire 100% of MicroDoz Therapy Inc., which has an exclusive partnership and license with a world leading university to conduct a landmark study into the efficacy of psilocybin assisted treatment of cannabis use disorder.
COMPASS Pathways granted fifth US patent for crystalline psilocybin
COMPASS Pathways plc announced today that it has been granted its fifth patent by the US Patent and Trademark Office.
Inside The Race To Create A Two-Hour Psychedelic Therapy Experience
The present article discusses the current race to shorten the psychedelic experience, which can last up to 10 hours with drugs like LSD, to two hours all while achieving the same therapeutic outcomes
MDMA and psychotherapy in combination could be used to treat alcoholism
Awakn Life Sciences is using an Imperial study into MDMA-assisted psychotherapy to create a treatment for alcoholism that it aims to offer in clinics.
1st Trial of Anesthetic Ketamine for Depression in Parkinson’s Wins $2M
Two scientists at Yale University were awarded $2 million from the Michael J. Fox Foundation to conduct the first clinical trial investigating the use of ketamine — a powerful anesthetic — as a treatment for depression in people with Parkinson’s disease.
H.C. Wainwright Stick to Their Buy Rating for ATAI Life Sciences
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on ATAI Life Sciences on Monday, setting a price target of $50, which is approximately 329.18% above the present share price of $11.65.